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to human research: the result is more animal-
based research
Mark J Rice
Abstract
Biomedical research today can be generally classified as human-based or nonhuman animal-based, each with
separate and distinct review boards that must approve research protocols. Researchers wishing to work with
humans or human tissues have become frustrated by the required burdensome approval panel, the Institutional
Review Board. However, scientists have found it is much easier to work with the animal-based research review
board, the Institutional Animal Care and Use Committee. Consequently, animals are used for investigations even
when scientists believe these studies should be performed with humans or human tissue. This situation deserves
attention from society and more specifically the animal protection and patient advocate communities, as neither
patients nor animals are well served by the present situation.
Background
This article seeks to explore and bind together four funda-
mental concepts: 1. Human-based research has been
neglected in favor of animal-based research. 2. Human-
based research offers clear benefits compared to animal-
based research. 3. Physician-scientists believe that Institu-
tional Review Boards (IRBs) are more difficult to deal with
than Institutional Animal Care and Use Committees
(IACUCs). 4. The difficulty in dealing with IRBs force
many physician-scientists, who prefer human research, to
perform research with animals.
Numerous groups have endorsed the reduction or
elimination of nonhuman animals (hereafter referred to
as animals) from research, but judging by the best esti-
mates, this has not happened [1-3]. Indeed, the number
of animals used in research is skyrocketing. Although the
exact number of animals used per year in the USA have
never been available, estimates for use in 1980 were
approximately 20 million [4]. Estimates now approximate
a half-billion [1,3] with genetically-modified animals
counting for the majority. Clearly, efforts to reduce the
total number of animals used in research have failed.
This failure has been explored by others [5-10]. The
explanations include, among others, tradition, institu-
tional inertia, the large amounts of money involved in the
process, the fact that it is statistically more likely to get
animal-based research funded by the National Institutes
of Health and other funding agencies than human-based
research, overall lack of societal concern for animals, and
animals in labs offer the researcher better control over
variables. I will introduce what I believe to be the first
essay proposing a regulatory-based explanation for the
continued use of animal models in university-based
r e s e a r c hi ns p i t eo fe v i d e n c et h a tt h e ym a yn o tb eg o o d
models for human disease: regulatory burden.
Greek and Greek’s recent article in this journal [7]
brought new attention to a 1986 National Academy Press
publication [11] that made public the fact that 50% or
more of all extramural NIH funding is directed toward
animal-based research. This is consistent with more
recent publications [12-18]. It is estimated that roughly
70% of the NIH research budget goes to basic science
[12,13] (which is animal intensive) and that the percen-
tage in the UK is approximately the same [14-18]. In
2003, Clinical Research Roundtable (CCR) at the
Institute of Medicine published a report in the Journal
of the American Medical Association stating that there is
a “disconnection between the promise of basic science
and the delivery of better health” [16]. The CRR also
pointed out that clinical research received about half the
Correspondence: mrice@anest.ufl.edu
Department of Anesthesiology, Department of Anesthesiology, University of
Florida College of Medicine, PO Box 100254, Gainesville, FL 32610-0254, USA
Rice Philosophy, Ethics, and Humanities in Medicine 2011, 6:12
http://www.peh-med.com/content/6/1/12
© 2011 Rice; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.money that basic science received [16], which is consis-
tent with the 70% figure for basic research funding cited
above.
Moreover, the amount of basic research being trans-
lated into human treatments appears to be at an all
time low [19-23]. An editorial in Nature [24] lamented
the fact that every week the scientific community hears
of animals being cured of some disease, but these
advances are not translating to humans. The pharma-
ceutical industry is also developing fewer new chemical
entities (NCEs) to test in the clinics [25].
I acknowledge that the use of animals in research is
contentious issue, both scientifically [2,5,8,9,26-29] and
ethically [30-39] with positions ranging from the animal
rightist Tom Regan to the equally adamant animal-based
research defender Carl Cohen. However, I am not an ani-
mal protectionist, welfarist, or rightist. I am a physician-
scientist, who prefers to do human clinical research. I
have migrated to this position, in part, because I now
question if animal-based research per se is predictive for
the human being modeled [2,8]. (See below for more on
this.) I am writing this article because I believe the animal
protection and patient advocacy communities are
neglecting an area which, if reformed, would help ani-
mals, humans, and researchers alike.
I spent the early part of my career as a physician-scien-
tist in the laboratory that developed the solution that is
now used throughout the world to preserve solid organs
for transplantation [40-44]. This was rewarding work,
resulting in saving thousands of lives because of the exten-
sion of organ viability prior to transplantation. Many ani-
mals were used in this process and much was learned
from their use. For a number of reasons, as my career pro-
gressed, I became more interested in doing human clinical
research. One reason was my disillusionment with using
animals to model human conditions. Sometimes, animal
models worked very well but many times they did not–the
problem was that prospectively we didn’t know into which
category the laboratory work would fall. It seemed my
time, effort, and valuable resources could be better spent
working directly with humans.
My concerns have been substantiated in the scientific
literature. Spanhaak et al. analyzed Medline abstracts and
European Public Assessment Reports, published by the
European Medicines Agency (EMEA) to assess the ability
of animals to predict hepatotoxicity. They reported a
false negative rate of 269 out of 710 (38%) compounds
based on Medline data and 70 out of 137 (51%) based on
EMEA data [45]. Johnson et al. discovered that out of 39
antineoplastic drugs tested on xenograft mice, only one
mimicked the response in humans [46]. Drugs used in
anesthesia are known to affect humans and animals dif-
ferently [47]. The denial of the effects of smoking [48]
and asbestos [49] were founded on studies in animals.
Many studies and commentaries have bemoaned the fact
that animal models cannot predict human response [50].
(I will address this more thoroughly below and for a
much more thorough examination of this issue see
[2,7,8].)
Our group has recently been successful in several
research areas including our recent debunking of a myth
regarding the anatomical nomenclature of the airway
[51]. In 2003, Smith and colleagues [52], using magnetic
resonance (MR) imaging, published a paper in one of our
leading journals stating that a long-held practice in
anesthesiology was unnecessary, and in fact possibly dan-
gerous. Cricoid pressure is used during the induction of
anesthesia by pressing on the airway, just below the thyr-
oid cartilage on the cricoid ring, to compress the alimen-
tary canal, preventing stomach contents from entering
the mouth and possibly the airway to the lungs. This
dreaded complication of anesthesia (aspiration) is fre-
quently fatal. Smith stated that the alimentary canal at
the level of the cricoid is the esophagus and they
attempted to show, through a series of MR images, that
the esophagus moved to the side during cricoid pressure
and in fact did not protect the airway during this
maneuver.
Our group, with one of the world’se x p e r t si nn e c k
anatomy as a coauthor, proved that the esophagus does
not even exist at the level of the cricoid. The alimentary
canal at this level is the post-cricoid hypopharynx, which
is important because this structure is fixed with respect
to the cricoid and does not move. The problem with the
previous Smith study was: 1. That the cricoid is superior
to the esophagus; thus pressure on it is not intended to
close off the esophagus, but also; 2. The cricoid pressure
unit is at the level of the cricoid and is attached to other
structures and thus, when pressure is applied, this pres-
sure translates straight down and the alimentary canal
can be closed off to prevent GI contents going into the
trachea and lungs.
This study was done in humans because we were
interested in the anatomy of ... humans. In addition, the
airways of the animals most commonly used in labora-
tories are not the same as the human airway [53-62]
and we believed animal imaging would have been of no
assistance in proving our hypothesis. While the above is
certainly anecdotal, the work referenced below confirms
my opinion that human-based research is superior to
animal-based research when the goal is diagnosis and
treatment of human disease.
Animals in Research
I have no ethical inhibition about using animals to find
cures for human disease. The current law allows using
animals in research and regulates the process; my con-
cern for their well-being stops there. Furthermore, there
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basic science research and I support such uses. For exam-
ple, animals can be, and historically have been, used as
heuristic devices, in basic research, as bioreactors, to
teach surgical procedures and so forth [2]. But using
them as predictive models or what has been called causal
analogical models [9], in applied research, such as drug
and disease research specifically, has not been a useful
exercise [2,8].
For example, in a Nature Medicine editorial introduc-
tion to two articles, one by by Van Dyke [63] and another
by Ellis and Fidler [64], the editorial stated: “The com-
plexity of human metastatic cancer is difficult to mimic
in mouse models. As a consequence, seemingly success-
ful studies in murine models do not translate into success
in late phases of clinical trials, pouring money, time and
people’sh o p ed o w nt h ed r a i n ” [64]. Ellis and Fidler sta-
ted: “Preclinical models, unfortunately, seldom reflect the
disease state within humans ...” [64]
One reason for the high cost of medications today is
the fact that drugs fail late in development. Only about
11% of all drugs entering Phase I human clinical trials
make it to the market (the failure rate for cancer drugs
is around 95%) [65]. Paul stated: “The higher failure
rates in these areas [cancer and drugs acting on the
CNS] are in part due to the relatively unprecedented
nature of the drug targets being pursued and to the lack
of animal models with a strong capacity to predict
human efficacy” [66]. A majority of drugs that enter
Phase III also fail. These failures are caused in large part
by the failures of the preclinical animal modes to predict
human responses[67-75]. The FDA has also acknowl-
edged this [76]. The other oft-overlooked factor is that
animal models have misled scientists into taking wrong
research paths and have perhaps kept treatments off the
market [77]. In my own field of anesthesiology there are
distinct differences in drug response among species [47].
Furthermore, animal testing has failed to prevent trage-
dies like the death of gene transplant recipient Jesse
Gelsinger [78] and the morbidity of the six volunteers
testing TGN1412 [71,79,80]. Wenner: “Wilson and the
rest of the scientific community had to learn the hard
way “that what you’ve learned from animals will not
necessarily predict what’s going to happen in humans"”
[78].
The animal model has been equally misleading in
research into mechanisms of diseases such as Alzhei-
mer’s [81-83], mesothelioma [84-86], smoking-induced
cancer [48,87], cancers in general [88,50,77], stroke
[89-91], HIV/AIDS [92-99] and others [100]. Even trans-
genic animal models have been disappointing [101,102].
A promising but greatly underfunded area of research
involves studying humans who, despite repeated expo-
sure to HIV, do not become infected [103].
One reason for the above failures is that humans vary
considerably in their response to drugs and even dis-
eases [104-113], thus expecting a different species to
predict human response is naïve. The question thus
arises: Why do scientists use animals when so much
research exists that can and should be performed with
humans or human tissue?
The goal of virtually all biomedical research is human
applications and it makes sense to study Homo sapiens.
G r a n te ta l .n o t e dt h a tt h e“United Kingdom spends
over £1600 million a year on non-commercial biomedi-
cal and health services research. The tacit understanding
is that the biomedical research these bodies support will
lead to an eventual improvement in health” [114]. Dor-
sey et al. [115] and Boat [116] both pointed out in 2010
that progress in biomedical research must be judged by
gains in the health of the human population. This tacit
understanding has implications for what sort of research
is funded. All good science is not ipso facto going to
advance medical care.
Rothwell [84] pointed out that studying humans and
the physical sciences have been the most productive
compared to animal research. He began by explaining
that 90% of non-National Health Service Research &
Development and non-industry funding in the UK came
from the Medical Research Council and three other cha-
rities (see table 1 [117] and figure 1 [118]). Of this fund-
ing, a very small percentage was spent on patient-
oriented clinical research. For example, the Wellcome
Trust spent less than 3.4% on diagnosis and treatment
evaluation. Others have also criticized the proportion of
funds spent on nonclinical research [119,120]. Rothwell
also condemned the British system for promoting basic
scientists to clinical chairs.B u t ,b r e a k t h r o u g h sd on o t
necessarily come from the target of resources. Rothwell:
Indeed, most major therapeutic developments over
the past few decades have been due to simple clinical
Table 1 Research expenditure of research funds by area
of research activity
Research Activity Percentage of research funding
MRC Wellcome BHF CRUK
Underpinning*
† 41.2 49.2 27.5 24.3
Aetiology
† 38.5 40.5 48.8 35.2
Prevention 2.9 1.9 1.8 2.1
Detection and diagnosis 4.5 1.7 6.0 6.1
Treatment development
† 5.6 4.3 9.3 17.3
Disease management 4.5 1.7 5.2 11.7
Health services 1.6 0.5 0.6 0.4
MRC = Medical Research Council, BHF = British Heart Foundation, CRUK =
Cancer Research UK. *Research aimed at understanding normal biological
development and functioning.
†Mostly laboratory-based.
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engineering rather than to laboratory-based medical
research. The clinical benefits of advances in surgery,
for example, such as joint replacement, cataract
removal, endoscopic treatment of gastrointestinal or
urological disease, endovascular interventions (e.g.,
coronary and peripheral angioplasty/stenting or coil-
ing of cerebral aneurysms), minimally invasive sur-
gery, and stereotactic neurosurgery, to name but a
few, have been incalculable. Yet only a fraction of
non-industry research funding has been targeted at
such clinical innovation. How much more might
otherwise have been achieved? [117]
Other studies support this opinion [119-123].
Rothwell goes on to point out that much of the failure of
basic research can be attributed to the use of animal mod-
els. Ledford continues this theme in discussing how Nobel
laureate Sydney Brenner brought an audience at the
American Association for Cancer Research to its feet
when he stated that Homo sapiens should be the model
organism for disease research. This is especially note-
worthy as Brenner won the Nobel Prize for his work on
Caenorhabditis elegans [124].
Additionally, there are risks to using animals in basic
research compared to studying humans in the clinical
arena. Alini et al. expressed concern that the use of some
animals models “... serve to spread incorrect information
about the processes involved in disc degeneration and
about the possibilities of repair” [125]. They continue:
If we want to improve understanding of pathology
and treatment of human IVDs [intervertebral discs],
legislation should change to allow us easier access to
human tissues, e.g. from pathological, cadaveric and
organ donor source. The fundamental question to be
addressed is: is it more (un)ethical to use animal
models, which we know do not represent any human
disc pathological conditions, or to use human tissues
with all the ethical issues? We collectively believe the
answer is clear: human tissue needs to be made more
available! [125] (Emphasis added.)
Why isn’t there more human tissue available for
study? I believe there is a critically important reason.
Protocol approval from local review boards:
IACUC and IRB
I want to contrast the ease of working through the regu-
latory framework for animal-based research, (approval
from the local IACUC), with the difficulty of the parallel
regulation involved in clinical research (approval from
the local IRB). I believe this is one major reason scien-
tists choose to work with animals instead of performing
clinical research–t h er e g u l a t o r yh u r d l ei ss i m p l ym u c h
lower.
Plous and Herzog [126] upset many in the scientific
community with a 2001 study published in Science.
They submitted protocols from one institution’s IACUC
to the IACUCs of a number of different institutions and
found that “regardless of whether the research involved
Figure 1 UK Health Research Analysis. Proportion of Combined Total Spend by Research Activity
Rice Philosophy, Ethics, and Humanities in Medicine 2011, 6:12
http://www.peh-med.com/content/6/1/12
Page 4 of 10terminal or painful procedures, IACUC protocol reviews
did not exceed chance levels of intercommittee agree-
ment.” Almost all protocols were approved at the local
IACUC, but were approved at other IACUCs only a
small percentage of the time. In other words, local
IACUCs favored the home research applicants, with
very easy protocol approval. They also showed that even
though almost all animal studies in their sample were
approved locally, the IACUC reviewers thought that
only 45% of these submissions were either good or
excellent. In addition, approximately 35% of the submis-
sions were either mostly not understood or not under-
stood at all. Finally, they deemed that 31% were either
not very valuable or not valuable at all. According to
the Plous study, IACUC approval is easy to obtain.
Perhaps Carbone, a veterinarian and long member of
an IACUC, since these were mandated in 1986, summed
up the role of the IACUC best when he stated that
IACUCs do not “function by rejecting animal protocols”
and that “this is especially true if a project has been
favorably peer-reviewed by a competitive granting
agency such as the NIH.” He concludes by stating that
“the current nature of animal protocol review, [is one]
in which virtually any research procedure may be
approved so long as it is justified by its scientific value”
[127] p183-4. I am not insinuating that the IACUC
approves everything without revisions or that they
unthinkingly rubberstamp alla p p l i c a t i o n s .B u ti nt h e
final analysis, the result is that a vast majority of every-
thing submitted ultimately gains approval and in a
timely fashion after the usual modifications.
In contrast to working with IACUCs, it is the opinion
of many physician-scientists that protocol approval from
IRBs is very difficult. Allow me to note that IRBs should
conscientiously and diligently protect human partici-
pants in research. The following are studies showing
just how costly–both in terms of time and money–
human-based research is and how difficult the naviga-
tion through the IRB process can be for researchers.
The Infectious Disease Society of America [128] pub-
lished a damning manuscript in 2009, outlining the tre-
mendous burden of current regulations on the progression
of human clinical research. They reported that local review
by IRBs of multi-center studies does not improve either
protocols or informed consents. Greene and Geiger stu-
died multiple IRB reviews of multicenter clinical trials and
observational studies. They reported a total of 40 peer-
review articles in addition to six reports from key sources.
They found vastly different requirements across various
IRBs [129]. Ravina et al “examined the costs and effects of
local IRB review of the consent and protocol in a multi-
center clinical trial in Parkinson disease.” The found that
“Seventy-six percent of changes to the consent [form]
reflected standard institutional language, with no
substantive changes to the protocol. The costs of this pro-
cess exceeded $100,000” [130].
Schneider et al. found that despite researchers’ use of
an IRB protocol and consent previously approved by
Harvard and Rand IRBs and the National Cancer Insti-
tute’s IRB, the IRB in 20 out of 65 institutions participat-
ing in a quality of care cancer study required changes to
the protocol resulting in time delays of more than one
year. Thirty-five required modification to the consent
form. Six IRBs required the researcher’s to obtain active
consent from the attending physician prior to contacting
the patent, which severely limited patient recruitment
[ 1 3 1 ] .F i n c he ta l .s t u d i e d7 5I R B sa n df o u n ds t u d i e s
associated with local IRBs had lower participation rates
and more effort was required to navigate the process
[132]. Green et al. reviewed IRBs for variation on obser-
vational health services research and concluded:
Several features of the IRB system as currently con-
figured impose costly burdens of administrative
activity and delay on observational health services
research studies, and paradoxically decrease protec-
tion of human subjects. Central review with local
opt-out, cooperative review, or a system of peer
review could reduce costs and improve protection of
human subjects[133].
The above themes have been echoed in numerous
other studies [129,134-141].
Inter-IRB variability has been well established and stu-
dies of individual IRBs also suggest that they require
changes that are arbitrary. It appears that very little is
being realized despite a process that is very resource con-
suming in terms of patient participation, time, and
money. Promotions in academia (at least in the USA) are
based on the number of papers published. One cannot
publish clinically-based research while waiting for the
local IRB to approve a protocol. It is my experience that
one can receive IACUC approval and accomplish a great
deal of research in the time it takes to get a single proto-
col IRB-approved. But, not only is the IRB process very
time-consuming, it is also very costly [130]. Dollars that
could be spent on research are unnecessarily channeled
into IRB preparation cost and these expenditures almost
never improve the research. Anecdotally, our department
has hired a professional just to handle IRB submissions
because of their difficulty. No such position is required
for IACUC submissions.
It is clearly necessary to have close oversight of
human clinical trials. The errors of days past, when
research subjects were abused, can never be repeated. I
believe that the current IACUC review system results in
sometimes-lax oversight, while the current IRB is an
absolute hindrance to medical advancement. As this
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address changes that might be appropriate for IACUCs.
I leave for others the challenge to steer animal-based
research protocols between the overly burdensome, irre-
levant, and adversarial regulation and the cozy old
buddy systems that merely rubber-stamps. However, the
incredibly burdensome IRB system, bogged down by
document minutia, has not been shown to be effective. I
am not advocating research without accountability. In
fact, I recently authored an opinion piece calling for the
naming an archiving author, whose responsibility it is to
keep all original research data for ten years following
publication [142]. This editorial, which is the first of its
kind, was partially in response to academic misconduct,
most famously portrayed by the Ruben anesthesia mis-
conduct scandal [143,144]. (The irony is that Ruben
conducted several studies without IRB approval,
although he stated he received approval in the publica-
tions. The IRB process did not protect patient welfare as
it was intended.)
The situation as it exists, however, is causing scientists
to use animals in research rather than work with human
models because of the large discrepancy in regulatory
ease between the two types of research. Based on dis-
cussions I have had with scientists in my university and
other universities where I have been a visiting professor
and or collaborator with other scientists, this problem is
real and is pushing many academics away from human
research. I realize that I have presented no hard evi-
dence that quantifies this problem. However, my hope is
that such studies will be done in the future and believe
that this article will stimulate such research. But the fact
that no such studies currently exist should not be taken
as proof my position is false. In medicine, case reports
have historically been used as harbingers of a brewing
problem on the horizon. My position is based on com-
munication with many scientists, in many different insti-
tutions (personal communication) and is supported by
studies examining overlapping areas.
Another personal note: I am currently involved in
evaluating a potential blood coagulation product. The
advice from established local researchers was to test the
concept in vivo in rabbits, then in dogs. As the product
is designed to test blood for certain properties, I sug-
gested that we study human blood in a much more rele-
vant in vitro model, avoiding many of the known and
unknown animal blood interferences. The knee-jerk
reaction is to test with an animal model even when test-
ing on human tissue (like blood) would be easier and
clearly more clinically applicable.
Human-based research
The above must be considered in light of the fact that
research and the practice of medicine are now focusing
on the differences between individual humans [106,107,
109,145-158], not the commonalities between humans
and other animals. Furthermore, NIH and other granting
bodies are actively pushing translational research. But
even translational research, when based on animal stu-
dies, has been problematic. Höerig and Pullman cau-
tioned that translational research is based on the premise
that in vivo animals studies can be translated to humans
but that “animal models themselves have a poor record
of predicting human disease outcome ...” [159]
Some believe the basis for beginning first-line research
should be human observation, not animal studies. Mar-
incola [160] noted that the scientific establishment cur-
rently favors research in the form of hypothesis testing
but ignores the fact that good hypotheses come from
the observation of humans. Without a good hypothesis
to test, the entire exercise becomes suspect. Marincola
goes on to describe why human observation should be
h e l di nh i g h e re s t e e ma n ds h o u l dn o tb ed i s m i s s e da s
“just descriptive.” He also notes: “For example, in animal
models, Interleukin-23 can either promote or hamper
cancer growth; yet, information about its bio-availability
in human cancers and its modality of expression, infor-
mation that can potentially provide insight into the
interpretation of such models, is limited” [160].
There appears to be a certain blindness to this pro-
blem and a frantic effort to find explanations for the
animal-model failure. Ioannidis presents a good example
of this mindset:
T h e r ei sc o n s i d e r a b l ee v i d e n c et h a tt h et r a n s l a t i o n
rate of major basic science promises to clinical appli-
cations has been inefficient and disappointing. The
deficiencies of translational science have often been
proposed as an explanation for this failure. An alter-
native explanation is that until recently basic science
advances have made oversimplified assumptions that
have not matched the true etiological complexity of
most common diseases... [161]
As Ioannidis states, “Even the most promising findings
of basic research take a long time to translate into clini-
cal experimentation, and adoption in clinical practice is
rare” [19]. Jin and Wang echo this when they point out
that pathologies in humans represent complex genetic
diversity while animal models are usually inbred strains.
They also correctly point out that treatments developed
in animals rarely succeed in humans [162].
Conclusion
This paper has tied together the following four concepts:
1. Human-based research has been neglected in favor of
animal-based research. 2. Human-based research offers
clear benefits compared to animal-based research. 3.
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Boards (IRBs) are more difficult to deal with than Insti-
tutional Animal Care and Use Committees (IACUCs)
and available evidence supports this. 4. The difficulty in
dealing with IRBs forces many physician-scientists, who
prefer human research, to perform research with
animals.
I believe this is the first essay proposing a regulatory-
based explanation for the continued use of animal mod-
els in university-based research in spite of evidence that
they may not be good models for human disease.
Research has shown that local IACUCs approve essen-
tially everything they consider. This is not to say IACUCs
are a rubber stamp, rather that the scientist working with
them can be confident of eventual approval. While there
is variation among IACUCs, a scientist applying for per-
mission for animal-based research can be more confident
than the scientist applying through the local IRB that the
protocol will be approved. This has implications for
scientists in the initial stage of their career must decide
between pursuing a career that involves human-based
research or animal-based. It also has implications for
experienced scientists who tire of the bureaucratic pro-
cess that involves IRBs. Scientists who need to attract
funding for their research will naturally be attracted to
the path of least resistance in order to receive approval
for their medical research projects. The much easier
approval of IACUC compared to IRB protocols offers a
number of obvious advantages including bringing money
into the university as well as more publications per year -
the most important key to academic promotion. The var-
iation among IACUCs per Plous and Herzog is probably
similar to that among IRBs (more research is needed).
However, the implications for this differ. The human-
based researcher may need to deal with multiple IRBs
simultaneously during multicenter trials while the ani-
mal-based researcher has only the local IACUC to con-
sider. In addition, the IRB appears to be far less efficient,
more costly, and imposes a more intricate, arbitrary, and
difficult regulatory burden even if the scientist is only
dealing with his local IRB.
I acknowledge that much more research needs to be
performed in order to provide adequate evidence to jus-
tify my conclusions. This is but an introductory paper,
not be the final word on anything, as I have obviously
not answered most let alone all the questions. A PubMed
search for “"Institutional Animal Care and Use Commit-
tee” and “Institutional Review Board"” revealed four
papers, none of which were relevant to this topic. Studies
are needed that survey those in the scientific community
who have worked with both the IRB and the IACUC ask-
ing specifically about the comparative difficulty of work-
ing with each. Research should also be conducted
comparing the length of time and number of changes
required between the two review panels. Comparison
could be made between the first application and final
approved application. The applications could then be
submitted to third party review panels for review and
judging as was done in the Plous study [126]. Surveys
could be performed among young physicians contemplat-
ing research careers in an attempt to ascertain why the
physicians choose to study animals or humans. Follow up
surveys could also be attempted five years later to see
how the plan played out. Nevertheless, this introduction
offers a reasonable, testable and novel explanation for
current thinking among physician-scientists.
As long as animal-based studies are funded to the
neglect of human-based studies and animal-based studies
reward the research institution with high overhead costs,
there will be pressure to migrate toward animal studies. In
order for a long-term satisfactory solution to be reached,
t h ef u n d i n gp r o c e s sa saw h o l em u s tb ea d d r e s s e d .T h a t
being said, we should not wait for a perfect solution before
implementing a better system. Standardizing IRBs would
be such a step in the right direction. The National Cancer
Institute’s( N C I ’s) Central Institutional Review Board
(CIRB) was studied by Wagner et al. This board functions
as a central review board to conduct a single review for
the NCI’s multisite phase III oncology trials. They found
that “CIRB affiliation was associated with faster reviews ...
fewer hours of research staff effort ... a savings of [money]”
[163].
In the final analysis, society must voice its support for
safe human-based research. This outcome can be facili-
tated by physician-scientists speaking out on the impor-
tance of our research both in the scientific literature and
in public forums. Humans volunteering to participate in
clinical research deserve the best protection available.
However, IRBs have become so onerous that physician-
scientists are being forced to rethink human research. In
contrast, it has been shown that IACUCs approve essen-
tially all local protocols. Neither situation is optimal, but
if a scientist is contemplating research with humans or
with animals, the disparity in regulatory bodies has and
will continue to influence the decision-making process.
Animal protectionists seeking to redirect scientists from
animals-based research to human-based research should
become involved with their local IRB. There is a universal
requirement that local leaders, from all walks of life, join
local IRBs. Animal protectionists can certainly participate
on these boards and as a member of the local commu-
n i t y ,c o n t r i b u t et ot h e i rf u n c t i o n i n g .T h i se s s a yh a sp r e -
sented one more important reason to participate.
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